AstraZeneca R&D executive Morrison to lead cancer firm Syndax

LONDON, June 15 (Reuters) - AstraZeneca's outgoing chief medical officer and head of global late-stage drug development Briggs Morrison, whose departure from the British drugmaker was announced last week, is to head U.S. cancer firm Syndax Pharmaceuticals.